Canine ALL patients, in addition to the canine B-cell leukemia cell line, GL-1, contain FLT3 mutations that lead to FLT3 up-regulation and subsequent activation of members of the JAK/STAT and MAP kinase pathways. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.